Tolvaptan for Treatment of Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) in a Child with Corpus Callosum Agenesis.

Abstract

Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is one of the common causes of euvolemic hyponatremia (serum Na+ < 135 mEq/L) in hospitalized children. It is characterized by increased serum ADH, leading to water retention via its action on V2 receptors in the distal renal tubules. Various conditions such as pain, the postoperative state, drugs, central nervous system infections, tumors, malformations, and pneumonia can predispose a person to SIADH. The conventional treatment of SIADH includes fluid restriction and salt supplementation. Occasionally, this may fail to control hyponatremia, mandating pharmacological therapy. V2-receptor antagonists are an FDA-approved therapy for adults with euvolemic and hypervolemic hyponatremia. However, there is limited experience with their use in the pediatric population. Here, the authors present a girl with corpus callosum agenesis with severe symptomatic hyponatremia due to SIADH who was successfully managed with the V2-receptor antagonist tolvaptan.

• Authors: Ankit Kumar Meena, Pamali Mahasweta Nanda, Rajni Sharma, Biswaroop Chakrabarty, Sheffali Gulati
• Journal: Indian journal of pediatrics (Indian J Pediatr) (Feb 09 2023) ISSN: 0973-7693 [Electronic] India
• PMID: 36757652 (Publication Type: Journal Article)
• Copyright: © 2023. The Author(s), under exclusive licence to Dr. K C Chaudhuri Foundation.